title: In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572.
abstract: In this study of nine clinical isolates obtained from integrase inhibitor-naïve HIV-2-infected patients, the median EC₅₀ value for the new integrase inhibitor S/GSK1349572 was 0.8 nM (range 0.2-1.4), and is similar to HIV-1 reference strains. We found a seven-, 13- and 18-fold increase in EC₅₀ values to S/GSK1349572 for the HIV-2 double (T97A + Y143C; G140S + Q148R) and triple (G140T + Q148R + N155H) mutants, respectively, obtained from two raltegravir-experienced patients.
authors.affiliation: Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Université Paris-Diderot, France.
authors.forename: Charlotte
authors.initials: C
authors.lastname: Charpentier
authors.forename: Lucile
authors.initials: L
authors.lastname: Larrouy
authors.forename: Gilles
authors.initials: G
authors.lastname: Collin
authors.forename: Florence
authors.initials: F
authors.lastname: Damond
authors.forename: Sophie
authors.initials: S
authors.lastname: Matheron
authors.forename: Geneviève
authors.initials: G
authors.lastname: Chêne
authors.forename: Ting
authors.initials: T
authors.lastname: Nie
authors.forename: Raymond
authors.initials: R
authors.lastname: Schinazi
authors.forename: Françoise
authors.initials: F
authors.lastname: Brun-Vézinet
authors.forename: Diane
authors.initials: D
authors.lastname: Descamps
mesh_terms: D024882:Drug Resistance, Viral / Q000187:drug effects / Q000235:genetics*; D015658:HIV Infections / Q000188:drug therapy / Q000235:genetics*; D019428:HIV Integrase Inhibitors / Q000494:pharmacology*; D015498:HIV-2 / Q000187:drug effects / Q000302:isolation & purification*; D006801:Humans; D009154:Mutation
chemical_list: D019428:HIV Integrase Inhibitors